77. Growth hormone secreting pituitary adenoma
1 clinical trial, 1 drug (DrugBank: 1 drug), 2 drug target genes, 19 drug target pathways
Searched query = "Growth hormone secreting pituitary adenoma", "Pituitary growth hormone secretion hyperthyroidism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800017714 | 2019-01-01 | 2018-08-10 | The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgery | The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgery | Growth Hormone-secreting Pituitary Adenoma (GH-PA) | Bromocentine Group:bromocentine mesylate tablet, starting dose is 0.625-1.25mg/d and the weekly increase of 1.25mg/d until 10-15mg/d.;Bromocentine and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of bromocentine mesylate tablet;Gamma Knife Radiosurgery Group:Gamma Knife Radiosurgery;Gamma Knife Radiosurgery and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of gamma knife radiosurgery; | Department of Endocrinology, Second Affiliated Hospital of Army Medical University | NULL | Pending | 18 | 70 | Both | Bromocentine Group:10;Bromocentine and Metformin Group:10;Gamma Knife Radiosurgery Group:10;Gamma Knife Radiosurgery and Metformin Group:10; | China |